SCHEMBL4101345

SCHEMBL4101345

Cn1c(=O)c(-c2ccccc2Cl)cc2cnc(NC3C4CN(C(=O)O)CC43)nc21

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 2/20 0.63
LCK P06239 1/20 0.63
FGFR1 P11362 6/20 0.53
ABL1 P00519 2/20 0.53
RIPK2 O43353 2/20 0.52
ACVR1 Q04771 2/20 0.52
NOD2 Q9HC29 2/20 0.52
WEE1 P30291 8/20 0.52
SRC P12931 3/20 0.52
EGFR P00533 3/20 0.52
FGFR2 P21802 1/20 0.52
FGFR4 P22455 1/20 0.52
FGFR3 P22607 1/20 0.52
PDGFRB P09619 1/20 0.49
KIT P10721 1/20 0.49
PDGFRA P16234 1/20 0.49
PAK1 Q13153 1/20 0.49
SIK1 P57059 1/20 0.48
SIK2 Q9H0K1 1/20 0.48
SIK3 Q9Y2K2 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4084178 0.93 MAPK14 (0.63) MAPK14LCKFGFR1ABL1RIPK2
SCHEMBL4089649 0.89 MAPK14 (0.59) MAPK14LCKFGFR1ABL1RIPK2
SCHEMBL13849317 0.89 LCK (0.59) MAPK14LCKFGFR1ABL1RIPK2
SCHEMBL4095453 0.88 MAPK14 (0.58) MAPK14LCKFGFR1ABL1RIPK2
SCHEMBL4088381 0.88 MAPK14 (0.55) MAPK14LCKFGFR1ABL1RIPK2
SCHEMBL4094757 0.88 LCK (0.50) MAPK14LCKFGFR1ABL1RIPK2
SCHEMBL4089651 0.87 MAPK14 (0.57) MAPK14LCKFGFR1ABL1RIPK2
SCHEMBL4084253 0.86 MAPK14 (0.62) MAPK14LCKFGFR1ABL1RIPK2
SCHEMBL13849299 0.86 MAPK14 (0.55) MAPK14LCKFGFR1ABL1RIPK2
SCHEMBL4095165 0.86 MAPK14 (0.55) MAPK14LCKFGFR1ABL1RIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-21 US claimed
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-21 US disclosed
EP-1831215-A1 PYRIDO[2,3-D]PYRIMIDINES AS ANTI-INFLAMATORY AGENTS Ranbaxy Laboratories Limited (IN) 2007-09-12 EP disclosed
WO-2006056863-A1 PYRIDO’2, 3-D!PYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS TLR1, TPMT, NOD1 MAPK14 3185/4885LCK 568/4885FGFR1 1184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.